

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL                                 |           |
|--|-----------|
| OMB Number:                                  | 3235-0287 |
| Estimated average burden hours per response: | 0.5       |

|  |  |  |  |  |  |  |  |  |
|--|--|--|--|--|--|--|--|--|
| 1. Name and Address of Reporting Person *<br><u>Van Plew Daniel P</u><br>_____<br>(Last) (First) (Middle)<br><u>777 OLD SAW MILL RIVER ROAD</u><br>_____<br>(Street)<br><u>TARRYTOWN NY 10591</u><br>_____<br>(City) (State) (Zip) |  |  | 2. Issuer Name and Ticker or Trading Symbol<br><u>REGENERON PHARMACEUTICALS, INC. [ REGN ]</u> |  |  | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)<br>Director 10% Owner<br><input checked="" type="checkbox"/> Officer (give title below) Other (specify below)<br><u>EVP &amp; General Mgr Industrial O</u> |  |  |
|  |  |  | 3. Date of Earliest Transaction (Month/Day/Year)<br><u>02/25/2020</u>                          |  |  |  |  |  |
|  |  |  | 4. If Amendment, Date of Original Filed (Month/Day/Year)                                       |  |  | 6. Individual or Joint/Group Filing (Check Applicable Line)<br><input checked="" type="checkbox"/> Form filed by One Reporting Person<br>Form filed by More than One Reporting Person  |  |  |

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) |   | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |            |                         | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|-------------------------|---|--|---|
|                                 |                                      |  | Code                           | V | Amount  | (A) or (D) | Price                   |   |  |   |
| Common Stock                    | 02/25/2020                           |  | M                              |   | 32,735  | A          | \$30.63                 | 60,986  | D  |   |
| Common Stock                    | 02/25/2020                           |  | F                              |   | 17,093  | D          | \$447.3                 | 43,893  | D  |   |
| Common Stock                    | 02/26/2020                           |  | S                              |   | 200   | D          | \$451.61 <sup>(1)</sup> | 43,693  | D  |   |
| Common Stock                    | 02/26/2020                           |  | S                              |   | 300   | D          | \$452.53 <sup>(2)</sup> | 43,393  | D  |   |
| Common Stock                    | 02/26/2020                           |  | S                              |   | 1,000   | D          | \$453.57 <sup>(3)</sup> | 42,393  | D  |   |
| Common Stock                    | 02/26/2020                           |  | S                              |   | 711   | D          | \$454.53 <sup>(4)</sup> | 41,682  | D  |   |
| Common Stock                    | 02/26/2020                           |  | S                              |   | 1,300   | D          | \$455.5 <sup>(5)</sup>  | 40,382  | D  |   |
| Common Stock                    | 02/26/2020                           |  | S                              |   | 1,435   | D          | \$456.5 <sup>(6)</sup>  | 38,947  | D  |   |
| Common Stock                    | 02/26/2020                           |  | S                              |   | 3,787   | D          | \$457.59 <sup>(7)</sup> | 35,160  | D  |   |
| Common Stock                    | 02/26/2020                           |  | S                              |   | 5,274   | D          | \$458.45 <sup>(8)</sup> | 29,886  | D  |   |
| Common Stock                    | 02/26/2020                           |  | S                              |   | 1,425   | D          | \$459.33 <sup>(9)</sup> | 28,461  | D  |   |
| Common Stock                    | 02/26/2020                           |  | S                              |   | 210   | D          | \$460.3 <sup>(10)</sup> | 28,251  | D  |   |
| Common Stock                    |                                      |  |                                |   |   |            |                         | 1,537   | I  | By 401(k) Plan  |

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |   | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |        | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                 | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |       |
|--|--|--------------------------------------|--|--------------------------------|---|--|--------|--|-----------------|---|--|--|---|--|-------|
|  |  |                                      |  | Code                           | V | (A)  | (D)    | Date Exercisable   | Expiration Date |   |  |  |   |  | Title |
| Non-Qualified Stock Option (right to buy)  | \$30.63  | 02/25/2020                           |  | M                              |   |  | 32,735 | (11)   | 12/14/2020      | Common Stock  | 32,735                                     | \$0.0  | 0   | D  |       |

**Explanation of Responses:**

- Represents volume-weighted average price of sales of 200 shares of Company stock on February 26, 2020 at prices ranging from \$451.51 to \$451.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
- Represents volume-weighted average price of sales of 300 shares of Company stock on February 26, 2020 at prices ranging from \$452.25 to \$452.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
- Represents volume-weighted average price of sales of 1,000 shares of Company stock on February 26, 2020 at prices ranging from \$453.06 to \$453.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
- Represents volume-weighted average price of sales of 711 shares of Company stock on February 26, 2020 at prices ranging from \$454.02 to \$454.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
- Represents volume-weighted average price of sales of 1,300 shares of Company stock on February 26, 2020 at prices ranging from \$455.01 to \$455.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.

6. Represents volume-weighted average price of sales of 1,435 shares of Company stock on February 26, 2020 at prices ranging from \$456.00 to \$456.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
7. Represents volume-weighted average price of sales of 3,787 shares of Company stock on February 26, 2020 at prices ranging from \$457.00 to \$457.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
8. Represents volume-weighted average price of sales of 5,274 shares of Company stock on February 26, 2020 at prices ranging from \$458.00 to \$458.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
9. Represents volume-weighted average price of sales of 1,425 shares of Company stock on February 26, 2020 at prices ranging from \$459.02 to \$459.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
10. Represents volume-weighted average price of sales of 210 shares of Company stock on February 26, 2020 at prices ranging from \$460.00 to \$460.60. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
11. The option became exercisable with respect to all shares underlying the option on December 31, 2013, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2013.

/s/\*\*Daniel P. Van Plew

02/27/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**